Amarin Corp Plc (AMRN)

[couldbebetter]

Birdbrain, I don't believe AMRN has to prove sales before a BO could
happen. It is really up to whatever BP is interested in AMRN to model
what they believe their sales of Vascepa could be if they owned it.
My guess is that Europe by itself could be worth $20 a share with the
right BP. Keep in mind that the exclusivity period in Europe is
limited. The sooner a BP is able to have their sales teams and
distribution network to get established, the more money they are
likely to make. Presuming the government health care systems
cover most of the cost for CVD patients, the patients using the
drug should be like an annuity for the BP...assuming the patients
continues taking the drug for as long as possible. In the US,
many patients stop using after 6 months for various reasons, so
the results in Europe (and Canada) should show a much longer
period of use. So there is actually more incentive for a BP
to acquire AMRN early on, at least for the value of Europe.